Richard B. BrewerKen MallonGerard ManningJinfeng LiuSascha RutzRandall J. BrezskiWael A. SalamehHak-Kim ChanDavid CipollaRichard BourgonJosé G NapolitanoClaudio ErraticoJustus B. CohenEduardo B. MartinsSimon S GaoAndrea CochranAaron H NileDaniel J. AndersonPatrick G HolderF. Anthony RomeroGuanglei ZhuangKamal Kishore JoshiKristine NovakQiuting HongJennifer CookVishva DixitMalcolm P HuestisShrirang RanadeTushar BhangaleNathan H KipnissJoseph W. LubachJorge Z. TorresMark R. LacknerBrad FriedmanDavid V HansenRobin G. LorenzShan ChungKushal SuryamohanChong HanChia-Lin Hsu
P108
P1830
P69
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia (1999-12-31)Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate CancerEffects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple SclerosisStudy of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE)Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerStudy of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 SignalingEfficacy of Tocilizumab on Patients With COVID-19A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic MelanomaAdjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating TumStudy of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)Ocrelizumab in Breastmilk
P767
An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic AtrophyAn Expanded Access Program of Emicizumab in Participants With Hemophilia A With InhibitorsA Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal CancerA Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaA Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced AsthmaA Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With ErlotinibA Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's LymphomaA Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid ArthritisA Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)An Observational Study of the Use and Safety of Xolair® During PregnancyA Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid TumorsA Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid TumorsA Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid TumorsStudy to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian CancerStudy to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative ColitisA Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial CarcinomaA Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier CohortA Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung CancerA Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's LymphomaA Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy VolunteersA Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerA Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's DiseaseA Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal CancerA Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic TherapyA Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following ChemotherapyA Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390gA Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast CancerA Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerA Continued Access Protocol to Provide Xolair to Patients With Severe Allergic AsthmaAn Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g
P859
Q16019312-CDBE77C6-4022-47C3-B49A-B8685205DB2FQ20743242-75179eaf-4296-6658-1534-70805cd54079Q28958324-e57b63ab-4dd5-d8e1-76d0-c13772cab28aQ30348390-73BCE2B1-B119-4958-8ABB-F23B88BC5398Q30582823-827E6ABD-F39E-4E01-8DFD-49B61100737BQ37384538-D437033A-352E-4B3B-B69C-6EFEF4000FE5Q37830953-448BA920-E6B3-484E-8F91-DF60FFF82E2AQ37834379-42B02BCC-FFBA-4868-87D6-688F2F7EAE52Q37837470-F38AD3F8-8443-4290-BDBB-4EAB0EA94987Q39183873-5D03996E-384B-4E61-B2CD-B79953D65853Q39902809-5C37B8BE-CF99-4C85-8D4B-8A077927BC2DQ41278453-0AC839B7-7D6D-4EE0-87E5-65D78C2BF592Q41806938-1EC34D19-2F9F-44BF-9E07-AAD2052668A8Q42185017-41E0A518-8266-4960-8FA4-D4CAA4C33A58Q42533755-F09F6260-FD6D-486F-941B-10B166254F91Q42700157-B1148A98-4396-4979-9C7A-CF040D34A98CQ42736135-DB53EF03-3F5C-487B-8F59-21D358D685B8Q42824859-2B991BCC-05BB-43DF-B6C9-0E907DE0414CQ42851823-5EFA0B54-A031-4DE5-ABB0-380328D5BE8DQ43151542-E9A0A22C-048E-43E7-9E79-2B8F88DD6EFFQ43182764-0D81607A-301B-42C8-8561-D3AD3161000FQ43227290-81E5D61D-9136-4E5D-9F55-6A898445853AQ44181202-71764B81-52AD-4533-B1F1-1CB7C7D527B6Q44260831-1951BF69-8FC2-48EE-88D5-8F45C9119D19Q45749359-D796268D-EA7E-492A-9BE8-2DF448191638Q45845575-fc7f0267-40dc-934d-568a-0302d3009739Q46548037-77988CDF-F52C-4293-B1ED-D8AB847F74EFQ46694986-450A1A8F-C74D-4BEC-8D02-E2861AF91084Q47036898-46b6c03a-46a6-d1f9-fcbc-06f7983382d0Q47142629-591E5272-D4B8-4B19-8F1E-5EE3B73D3950Q47226874-b5ba85b6-4c86-4e6e-ef25-3fce13f80600Q47474680-EBADFB38-EDBF-422B-B00B-D7F35D4B1EDEQ47824600-E22EEA67-CC06-4716-9135-3B4D44F26D7EQ48226968-50F097B6-700F-40DD-9472-3EF5B1AD281BQ48594993-9D547C95-B0B2-45B4-BCBE-EF60B3281A9EQ50229441-C1EE401D-852A-4C4C-9D5C-F97A7D9F889AQ51039432-3C454F0F-618F-4574-81CF-1C18AAD950DDQ51733962-641520F7-5317-40C7-B8AF-B23E192969F6Q51820110-2759DC42-C10B-49E2-AD27-3403381B36D8Q53394656-4D3F60BE-AEEC-4EB3-988F-4DC81E2BC429
P108
description
americká firma
@cs
bedrijf uit Verenigde Staten van Amerika
@nl
biotech company
@en
name
Genentech Inc.
@it
Genentech
@ca
Genentech
@de
Genentech
@en
Genentech
@en-ca
Genentech
@eo
Genentech
@es
Genentech
@eu
Genentech
@fi
Genentech
@fr
type
label
Genentech Inc.
@it
Genentech
@ca
Genentech
@de
Genentech
@en
Genentech
@en-ca
Genentech
@eo
Genentech
@es
Genentech
@eu
Genentech
@fi
Genentech
@fr
altLabel
Genentech Inc
@es
Genentech Inc
@nl
Genentech Inc.
@es
Genentech Inc.
@nl
Genentech
@it
Genentech
@zh
Genetic Engineering Tech Inc
@es
Genetic Engineering Tech Inc.
@es
Genetic Engineering Tech
@es
Genetic Engineering Technology
@nl
prefLabel
Genentech Inc.
@it
Genentech
@ca
Genentech
@de
Genentech
@en
Genentech
@en-ca
Genentech
@eo
Genentech
@es
Genentech
@eu
Genentech
@fi
Genentech
@fr
P6366
P646
P1056
P1128
P1417
topic/Genentech-Inc
P154
P213
0000 0004 0465 1775
P2427
grid.453714.0
P31
P3417
P373
P571
1976-01-01T00:00:00Z